Get the Stockscreener App
1.44
8.86%
-0.14
Pepgen Inc stock is traded at $1.44, with a volume of 188.74K.
It is down -8.86% in the last 24 hours and down -5.26% over the past month.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
See More
Previous Close:
$1.58
Open:
$1.54
24h Volume:
188.74K
Relative Volume:
0.07
Market Cap:
$47.12M
Revenue:
-
Net Income/Loss:
$-87.23M
P/E Ratio:
-0.4848
EPS:
-2.97
Net Cash Flow:
$-82.77M
1W Performance:
+4.35%
1M Performance:
-5.26%
6M Performance:
-66.67%
1Y Performance:
-89.63%
1-Day Range:
$1.40
$1.57
1-Week Range:
$1.33
$1.68
52-Week Range:
$0.8801
$19.30
Pepgen Inc Stock (PEPG) Company Profile
Name
Pepgen Inc
Sector
Industry
Phone
703-456-8000
Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
1.44 | 45.15M | 0 | -87.23M | -82.77M | -2.97 |
|
ONC
Beigene Ltd Adr
|
236.49 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.32 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.24 | 43.44M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.62 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.09 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-21-22 | Initiated | H.C. Wainwright | Buy |
Pepgen Inc Stock (PEPG) Latest News
PepGen appoints new CTO to advance therapies By Investing.com - Investing.com South Africa
PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stoc - GuruFocus
PepGen Appoints New CTO with Bluebird Bio Experience | BLUE Stock News - GuruFocus
PepGen appoints new CTO to advance therapies - Investing.com
PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer - New Castle News
PepGen Inc. (NASDAQ:PEPG) Holdings Lifted by Dimensional Fund Advisors LP - Defense World
PepGen Inc.’s Promising Advances in DMD and DM1 Programs Justify Buy Rating - TipRanks
PepGen Inc reports results for the quarter ended March 31Earnings Summary - TradingView
HC Wainwright Cuts PepGen (NASDAQ:PEPG) Price Target to $14.00 - Defense World
PepGen Inc. Reports Q1 2025 Financial Results - TipRanks
ATTENTION PEPG SHAREHOLDERS: Investors Who Lost Money on PepGen Inc. are Urged to Contact Levi & Korsinsky About an Ongoing Investigation - ACCESS Newswire
PepGen stock price target cut to $14 from $16 by H.C. Wainwright - Investing.com Nigeria
PepGen (PEPG) Stock Target Price Lowered by HC Wainwright & Co. - GuruFocus
PepGen (PEPG) Price Target Adjusted by H.C. Wainwright Analyst | PEPG Stock News - GuruFocus
PepGen (PEPG) Price Target Adjusted by H.C. Wainwright Analyst | - GuruFocus
PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - BioSpace
PepGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - Bluefield Daily Telegraph
PepGen Inc. CEO Makes Bold Stock Purchase! - TipRanks
Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
PepGen Inc.’s CEO Makes Bold Stock Purchase! - TipRanks
PepGen president and CEO McArthur buys shares worth $47,724 By Investing.com - Investing.com Canada
PepGen president and CEO McArthur buys shares worth $47,724 - Investing.com
PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
PepGen stock plunges to 52-week low of $1.14 amid market challenges - Investing.com Canada
PepGen stock plunges to 52-week low of $1.14 amid market challenges By Investing.com - Investing.com South Africa
PepGen (NASDAQ:PEPG) Stock Price Down 14.4% – Time to Sell? - Defense World
PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference - BioSpace
PepGen Announces Appointment of Two New Directors to its Board - BioSpace
PepGen Appoints Lisa Wyman and Mitchell Finer to its Board of Directors - citybiz
PepGen Inc. Expands Board with New Appointments - TipRanks
PepGen names two new directors to board - TipRanks
PepGen CMO Mellion resigns, effective April 4 - Investing.com Australia
PepGen CMO Mellion resigns, effective April 4 By Investing.com - Investing.com South Africa
Pepgen Inc Stock (PEPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):